Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (LTRN) leverages artificial intelligence and precision medicine to revolutionize oncology drug development. This news hub provides investors and researchers with timely updates on the company's progress in transforming cancer treatment through biomarker-driven approaches.
Access centralized, reliable information on clinical trial milestones, strategic collaborations, and regulatory developments. Our curated news collection simplifies tracking of AI-powered drug discovery advancements and therapeutic pipeline updates specific to Lantern Pharma's innovative platform.
Discover how machine learning accelerates oncology research while maintaining focus on genetic screening precision. The page serves as an essential resource for understanding the company initiatives shaping personalized cancer therapies.
Bookmark this page for streamlined access to verified announcements and analysis-free updates directly impacting Lantern Pharma's position in biotechnology innovation.
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announces significant milestones in the growth and development of its RADR® AI platform for cancer drug discovery. The platform has exceeded 60 billion data points and is expected to reach 100 billion by 2024. Lantern focuses on enhancing data growth efforts in drug sensitivity, combination treatment outcomes, biomarker data in rare cancers, and synthetic lethal targets. The company aims to improve molecular optimization, feature extraction, and drug-drug interaction predictions. RADR®'s expansion enables more precise cancer therapy development, automating data collection, and curation processes efficiently.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) achieves a significant milestone in its ADC program by developing a novel cryptophycin-based ADC with potent anti-tumor activity. The company collaborates with academic partners to create highly specific and effective ADCs for various solid tumor indications. Leveraging RADR® AI platform and a unique conjugation approach, Lantern aims to advance towards IND development in 2024, targeting unresponsive solid tumors. The cryptophycin ADC shows superior potency and tumor-killing capabilities compared to existing ADCs, offering a promising solution for cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
-
Rhea-AI Summary
Starlight Therapeutics, a Lantern Pharma subsidiary, has announced the appointment of Marc Chamberlain, M.D. as its Chief Medical Officer. Dr. Chamberlain will oversee clinical operations and planned clinical trials for brain cancers. He brings extensive expertise in neuro-oncology and therapeutic development, which will be invaluable for advancing Starlight's AI-enabled and accelerated drug development portfolio. Starlight is focused on developing precision therapeutics for cancers with limited or no effective therapeutic options, such as pediatric and adult brain cancers. The company is preparing for recurrent glioblastoma studies and has developed a CNS penetrant wholly synthetic acylfulvene, LP-184, for targeting brain tumors. The announcement marks a significant step in the company's mission to transform oncology with AI-enabled drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) has received Orphan Drug Designation (ODD) for LP-284 from the U.S. FDA for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements. The drug has shown potent anti-tumor activity in preclinical models and is being developed for several aggressive B-cell NHL, including MCL and HGBL. LP-284 received its second ODD this year, making a total of five orphan designations granted to Lantern. The ODD provides seven years of market exclusivity and eligibility for expedited drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announced FDA clearance for Phase 1 clinical trial for LP-284 in non-Hodgkin’s lymphomas, progress in Phase 2 LP-300 trial for lung cancer, and financial results for Q3 2023. The company's AI platform RADR® aims to revolutionize cancer drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.21%
Tags
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2023 operating and financial results webcast on November 8th at 4:30 p.m. ET. The company will discuss the operating and financial results for the third quarter, as well as provide guidance on upcoming milestones, clinical trials, and developments of its AI platform, RADR®. The webcast will be led by Panna Sharma, President and CEO of Lantern Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
Rhea-AI Summary
Lantern Pharma Inc. to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.32%
Tags
-
Rhea-AI Summary
Lantern Pharma announces in vivo data on drug candidate LP-184 in glioblastoma, validating its potential as a therapeutic for GBM. Phase 1 trial underway. LP-184 has a global market potential of $11-13 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.23%
Tags
-
Rhea-AI Summary
Lantern Pharma announces dosing of first patient in Phase 1 trial for LP-184, a potential therapy for advanced solid tumors and CNS cancers. LP-184 has a global market potential of $11-13 billion. Multiple clinical trial sites to be activated in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
Rhea-AI Summary
Lantern Pharma receives FDA clearance for LP-284 IND application, a drug candidate for non-Hodgkin's lymphoma, with a potential market value of $4 billion USD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
Lantern Pharma Inc
Nasdaq:LTRN
LTRN Rankings
LTRN Stock Data
33.54M
9.20M
14.72%
23.34%
2.15%
Biotechnology
Pharmaceutical Preparations
United States
DALLAS